PTK2 Antibody

What is PTK2 and what are its primary cellular functions?

PTK2, also known as focal adhesion kinase (FAK), is a 119.2 kDa cytosolic protein tyrosine kinase that plays crucial roles in cellular adhesion and spreading processes. As a member of the FAK subfamily of protein tyrosine kinases, PTK2 functions as a central mediator in focal adhesion dynamics between cells and the extracellular matrix .

The protein has diverse cellular roles including:

• Regulation of cell migration and motility

• Promotion of cell survival pathways

• Mediation of angiogenesis and axon guidance

• Involvement in mitogen response

• Participation in focal adhesion turnover

PTK2 is encoded by the PTK2 gene, which produces a canonical protein of approximately 1052 amino acid residues. The protein contains a large FERM domain and is highly conserved across species. While PTK2 lacks significant sequence similarity to kinases from other subfamilies, it shares similarities with other FAK subfamily members such as PYK2 .

What are the most common applications for PTK2 antibodies in research?

PTK2 antibodies are utilized across various research applications with Western blot being the most widely employed technique. According to the literature, there are over 2700 citations describing the use of PTK2 antibodies in research applications .

Common applications include:

When selecting an antibody for a specific application, researchers should verify the validation data for their particular application to ensure optimal results .

How is PTK2 expressed across different tissues and cell types?

PTK2 demonstrates a relatively broad expression pattern but with notable tissue-specific variations. The protein is expressed in most cell types with the exception of certain blood cells .

Tissue-specific expression includes:

• High expression in B and T-lymphocytes

• Notable expression in brain tissue (including corpus callosum)

• Expression in melanocytes

• Presence in placenta

• Expression in trachea

• Different expression patterns between leukocytes and keratinocytes

Expression level analysis can provide valuable insights in disease contexts. For example, PTK2 expression levels correlate with prognosis in uveal melanoma and idiopathic pulmonary fibrosis, making it a potential prognostic biomarker in these conditions .

What controls should be included when validating PTK2 antibody specificity?

When validating PTK2 antibody specificity, researchers should implement multiple controls to ensure reliable results:

• Positive tissue controls: Use tissues known to express PTK2 (e.g., T-cells, brain tissue) as positive controls

• Negative tissue controls: Include tissues with minimal PTK2 expression or use PTK2 knockout models where available

• Blocking peptide validation: Utilize the specific blocking peptide corresponding to the antibody's immunogen to confirm signal specificity

• Multiple antibody validation: Compare results using different antibodies targeting distinct PTK2 epitopes

• Cell-type specificity checks: Consider tissue-specific expression patterns when interpreting results—for example, PTK2 shows differential expression in leukocytes versus keratinocytes

• Cross-reactivity assessment: Check for cross-reactivity against related proteins, particularly other FAK family members

• Subcellular fractionation: Confirm that the detected protein appears in the expected subcellular compartment (primarily cytosolic for PTK2)

Implementing these controls helps distinguish genuine PTK2 signal from potential artifacts or cross-reactivity with other proteins.

How should I optimize Western blot protocols for detecting PTK2?

For optimal detection of PTK2 by Western blot, consider the following methodological considerations:

• Sample preparation:

  • Perform subcellular fractionation to enhance detection sensitivity

  • Use phosphatase inhibitors if detecting phosphorylated forms

  • Consider size exclusion chromatography (SEC) for complex samples to separate PTK2 from potentially cross-reactive proteins

• Gel electrophoresis:

  • Use 8-10% gels to properly resolve the 119-125 kDa PTK2 protein

  • Include molecular weight markers spanning 100-130 kDa range

• Antibody selection and dilution:

  • For total PTK2: Use antibodies targeting conserved regions

  • For phosphorylated PTK2: Select antibodies specific to phospho-sites of interest (e.g., Y576/Y577)

  • Optimize antibody dilution through titration experiments

• Signal detection:

  • Use enhanced chemiluminescence for general detection

  • Consider fluorescent secondary antibodies for multiplexing with other proteins

• Controls:

  • Include lysates from cells with known PTK2 expression (e.g., T-cells)

  • Consider using PTK2 knockout/knockdown samples as negative controls

  • For phospho-specific detection, include samples treated with phosphatase

Following these optimization steps will enhance specificity and sensitivity when detecting PTK2 by Western blot.

What are the key considerations for immunohistochemical detection of PTK2?

When performing immunohistochemistry (IHC) for PTK2 detection, researchers should consider:

• Fixation method:

  • Paraformaldehyde (PFA) is recommended due to superior tissue penetration

  • Prepare PFA fresh before use to prevent formation of formalin (which occurs when PFA molecules congregate during storage)

• Antigen retrieval:

  • Heat-induced epitope retrieval may be necessary, especially for formalin-fixed tissues

  • Optimize pH and buffer conditions based on the specific antibody requirements

• Antibody validation:

  • Confirm antibody reactivity in paraffin-embedded sections

  • Utilize both positive and negative control tissues

  • Consider dual staining with markers of expected co-localization

• Signal interpretation:

  • PTK2 is primarily found in cell junctions and focal adhesions

  • Expression in corpus callosum cell junctions has been reported

  • Be aware of subcellular localization differences between cell types

• Cross-tissue validation:

  • Compare expression patterns with known literature reports

  • Be aware that PTK2 localization may vary between tissues (e.g., primarily cytoplasmic in some cells, nuclear in others)

These considerations help ensure reliable and interpretable PTK2 immunohistochemical data.

How does PTK2 signaling contribute to cancer progression and therapy resistance?

PTK2 plays significant roles in cancer progression and therapy resistance through multiple mechanisms:

• Metastasis promotion:

  • PTK2 facilitates cell migration by regulating focal adhesion dynamics

  • When FAK was blocked, breast cancer cells showed decreased mobility and reduced metastatic potential

  • In uveal melanoma, PTK2 promotes metastasis by activating the epithelial-mesenchymal transition (EMT) process

• Therapy resistance mechanisms:

  • In non-small cell lung cancer (NSCLC), PTK2 hyperphosphorylation contributes to EGFR-TKI resistance through persistent Akt activation

  • Combined inhibition of PTK2 and EGFR may overcome resistance to EGFR-TKIs in NSCLC

• Prognostic significance:

  • PTK2 upregulation is associated with malignancy, metastasis, and poor survival in multiple cancers

  • PTK2 expression correlates with chromosome 8q gain in uveal melanoma, predicting poor prognosis

  • In chronic lymphocytic leukemia (CLL), higher PTK2 mRNA levels predict better response to rituximab-containing immunochemotherapy

• Therapeutic targeting:

  • Several clinical studies have been initiated on PTK2 inhibitors for patients with solid tumors

  • PTK2 inhibition can blunt rituximab-dependent cell death in vitro

These findings highlight PTK2 as both a prognostic biomarker and potential therapeutic target in various cancers, with complex context-dependent roles in treatment response.

How can I effectively detect PTK2 phosphorylation states?

Detection of specific PTK2 phosphorylation states requires careful methodological considerations:

• Key phosphorylation sites:

  • Y576/Y577: Critical for full kinase activation

  • Y397: Autophosphorylation site important for initiating kinase activity

  • Y925: Involved in interaction with Grb2

• Phospho-specific antibody selection:

  • Use antibodies specifically validated for phospho-epitopes

  • For detecting Y576/Y577 phosphorylation, anti-pPTK2 Y576/Y577 antibodies have been validated in research settings

• Sample preparation:

  • Immediate lysis in buffers containing phosphatase inhibitors is critical

  • Flash-freezing samples prior to processing helps preserve phosphorylation status

  • Avoid repeated freeze-thaw cycles that can reduce phospho-signal

• Validation approaches:

  • Phosphorylation array analysis can be used to measure multiple phosphorylation sites simultaneously

  • Compare phosphorylation levels across different conditions (e.g., control vs. treated cells)

  • Use of phosphatase treatment as a negative control

• Detection methods:

  • Western blotting with phospho-specific antibodies is the standard approach

  • Immunofluorescence can detect subcellular localization of phosphorylated PTK2

  • Flow cytometry may be used for cell-by-cell quantification

Detecting PTK2 phosphorylation is particularly important when studying signaling pathways activated in cancer and during cell migration processes.

What is the role of PTK2 in predictive biomarker development?

PTK2 has emerged as a potential predictive biomarker in several disease contexts:

• Idiopathic Pulmonary Fibrosis (IPF):

  • A PTK2-associated gene signature has been developed to predict disease prognosis in IPF patients

  • This signature strongly reflects activation levels of immune pathways and immune cells

  • Patients classified as high-risk by this signature showed decreased survival rates compared to low-risk patients

• Chronic Lymphocytic Leukemia (CLL):

  • Higher pretreatment PTK2 mRNA levels predicted greater benefit from rituximab-fludarabine-cyclophosphamide (R-FC) compared to FC alone

  • This finding was validated in two independent clinical trials (REACH and CLL8)

  • PTK2 expression was associated with improved outcomes independent of known prognostic factors

• Uveal Melanoma:

  • PTK2 expression, enhanced by chromosome 8q gain, correlates with poor prognosis

  • It serves as an independent risk factor predicting poor outcomes

  • The mechanism involves promotion of the EMT phenotype leading to metastasis

These studies demonstrate the potential utility of PTK2 as both a prognostic and predictive biomarker, informing treatment decisions and patient stratification in clinical trials.

How can I improve the sensitivity of PTK2 detection in complex samples?

Enhancing PTK2 detection sensitivity in complex samples requires specialized approaches:

• Subcellular fractionation:

  • Separate cellular proteins according to subcellular localization (cytosol, organelle, membrane, nuclear)

  • This approach enables detection of PTK2 in its physiological compartment (primarily cytosolic)

  • Subcellular fractionation combined with size exclusion chromatography (SEC) enables high-resolution detection of proteins and protein complexes

• Protein enrichment strategies:

  • Immunoprecipitation can concentrate PTK2 before detection

  • Using antibody pairs (one for immunoprecipitation, another for detection) can improve specificity

  • Commercial antibody pair sets are available specifically designed for this application

• Signal amplification methods:

  • Consider tyramide signal amplification for IHC/IF applications

  • Use high-sensitivity chemiluminescent substrates for Western blotting

• Specificity enhancement:

  • Compare reactivity across different cell types (e.g., leukocytes vs. keratinocytes)

  • Cell type-dependent reactivity profiles help interpret potential cross-reactivity

  • Analyze elution profiles to distinguish monomeric PTK2 from complexes

• Comparative analysis:

  • Compare results from different cell types with established PTK2 expression patterns

  • This approach helps distinguish genuine PTK2 signal from non-specific binding

These techniques have been successfully employed to detect PTK2 in complex biological samples while maintaining specificity and sensitivity.

What are common pitfalls in PTK2 antibody-based experiments and how can they be addressed?

Researchers should be aware of these common challenges when working with PTK2 antibodies:

• Cross-reactivity issues:

  • PTK2 antibodies may detect related family members (e.g., PYK2)

  • Solution: Validate antibody specificity using knockout/knockdown controls or multiple antibodies against different epitopes

• Isoform detection:

  • Up to 7 different isoforms have been reported for PTK2

  • Solution: Select antibodies targeting common regions for pan-isoform detection or isoform-specific regions when studying particular variants

• Subcellular localization artifacts:

  • PTK2 localization can vary by cell type and experimental conditions

  • Solution: Use proper subcellular fractionation and compare with published localization data

• Signal near void volume in SEC:

  • May represent cross-reactivity rather than genuine PTK2

  • Solution: Verify cell type-dependent reactivity to distinguish specific from non-specific signals

• Post-translational modification detection:

  • PTK2 undergoes multiple modifications including sumoylation and phosphorylation

  • Solution: Use modification-specific antibodies and appropriate controls (e.g., phosphatase treatment)

• BSA interference:

  • Some applications may be sensitive to BSA present in antibody formulations

  • Solution: Request BSA-free antibody preparations when necessary

Addressing these pitfalls through careful experimental design improves data quality and interpretability.

How should I select the appropriate PTK2 antibody for my specific research application?

Selection of the optimal PTK2 antibody requires consideration of multiple factors:

• Application compatibility:

  • Verify the antibody has been validated for your specific application (WB, IF, IHC, IP)

  • Some antibodies work well for certain applications but poorly for others

  • Review validation images and published data for your intended application

• Epitope selection:

  • For total PTK2: Antibodies targeting the C-terminus (e.g., 1024-1052aa) are commonly used

  • For phospho-specific detection: Select antibodies validated for specific phospho-sites (e.g., Y576/Y577)

  • Consider epitope conservation across species if working with non-human models

• Species reactivity:

  • Confirm the antibody's reactivity with your species of interest

  • PTK2 gene orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species

  • Sequence homology analysis can predict cross-reactivity for untested species

• Detection method:

  • For WB: Consider antibodies optimized for denatured proteins

  • For IF/IHC: Select antibodies that recognize native protein conformations

  • For IP: Choose antibodies with high affinity for the native protein

• Validation evidence:

  • Review manufacturer validation data for your application and sample type

  • Check literature citations using the antibody for similar applications

  • Consider antibody pairs for IP-WB applications

Following these guidelines will help ensure selection of an appropriate PTK2 antibody that provides reliable results for your specific research needs.

What emerging technologies are advancing PTK2 research?

Recent technological developments are enhancing our ability to study PTK2:

• PTK2-associated gene signatures:

  • Development of gene signatures based on PTK2-associated genes for prognostic and predictive applications

  • These signatures reflect activation levels of immune pathways and cells

• Combined therapeutic approaches:

  • Exploration of PTK2 inhibitors in combination with other targeted therapies

  • For example, combining PTK2 inhibitors with EGFR-TKIs to overcome resistance in NSCLC

• High-resolution antibody array analysis:

  • Combining subcellular fractionation, size exclusion chromatography, and antibody arrays

  • Enables detailed analysis of PTK2 expression and interactions across cellular compartments

• Phosphorylation array analysis:

  • Simultaneous measurement of multiple tyrosine kinase phosphorylation states

  • Allows comprehensive assessment of PTK2 activation in the context of broader signaling networks

These technologies are expanding our understanding of PTK2 biology and its potential as a therapeutic target and biomarker in various diseases.

How is PTK2 research influencing clinical applications?

PTK2 research is increasingly translating to clinical applications:

• Biomarker development:

  • PTK2 expression serves as a prognostic indicator in multiple cancers including uveal melanoma

  • PTK2-associated gene signatures predict IPF prognosis

  • PTK2 mRNA levels predict benefit from immunochemotherapy in CLL

• Therapeutic targeting:

  • Several clinical studies have been initiated on PTK2 inhibitors for solid tumors

  • PTK2 inhibitors effectively inhibited cancer growth in vitro and in vivo

• Combination therapy approaches:

  • Combined inhibition of PTK2 and EGFR may overcome resistance to EGFR-TKIs

  • This combination therapy represents a viable option for EGFR-TKI-resistant NSCLC

• Patient selection strategies:

  • PTK2 expression may serve as a useful biomarker for patient selection in future clinical trials

  • This approach could help identify patients most likely to benefit from specific therapeutic interventions